Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
暂无分享,去创建一个
Alan Brennan | Nick Bansback | Kaleb Michaud | Richard M Nixon | A. Brennan | F. Wolfe | K. Michaud | N. Bansback | A. Wailoo | R. Nixon | Allan J Wailoo | Fred Wolfe
[1] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[2] A. Brennan,et al. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. , 2007, Rheumatology.
[3] P. Geborek,et al. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden , 2003, Annals of the rheumatic diseases.
[4] V. Strand,et al. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. , 2002, Rheumatology.
[5] A. Laupacis,et al. A call for fairness in formulary decisions. , 2006, Archives of Internal Medicine.
[6] Alan Brennan,et al. Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis , 2007, Statistics in Medicine.
[7] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.
[8] A Woolf,et al. The links between joint damage and disability in rheumatoid arthritis. , 2000, Rheumatology.
[9] M. Weinstein,et al. Medicare and cost-effectiveness analysis. , 2005, The New England journal of medicine.
[10] A. Brennan,et al. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden , 2004, Annals of the rheumatic diseases.
[11] F. Wolfe,et al. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. , 2004, The Journal of rheumatology.
[12] A. Brennan,et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. , 2004, Rheumatology.
[13] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[14] Stephen Joel Coons,et al. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.
[15] Hyon K. Choi,et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. , 2003, Arthritis and rheumatism.